Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Recruiting
Observational Study
Kidney Transplant Rejection
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Virginia Commonwealth University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allograft injury. However, dd-cfDNA may lack sensitivity in certain clinical scenarios particularly in cas…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Prospective Inclusion Criteria:
* Age ≥18 years
* Undergoing a clinically indicated biopsy
* Able to provide informed consent
* Willing to provide a urine sample and allow access to relevant clinical
Retrospective Inclusion Criteria:
* Age ≥18 years
* Biopsy-confirmed rejection (positive histolog…
Contacts